{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261723","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.572363+00:00","generated_at":"2026-05-17T00:56:00.003656+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms","bullets":["Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.","Sokolove previously CMO-in-Residence at Roivant Sciences, SVP at GSK, Head of Immunology at AbbVie.","Vor Bio emphasizes Telitacicept (dual BAFF/APRIL inhibitor) as near-term opportunity for autoimmune patients.","Amended CDO Dr. Qing Zuraw's severance: pro-rated 2025/2026 target bonus if terminated w/o cause, or if resigns after Dec 31, 2025.","Employment amendment effective for five months from Nov 2, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261723","json":"https://secwatch.observer/filing/0001193125-25-261723.json","markdown":"https://secwatch.observer/filing/0001193125-25-261723.md","text":"https://secwatch.observer/filing/0001193125-25-261723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525261723/0001193125-25-261723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525261723/vor-20251102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:56:00.003656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}